ClinicalTrials.gg
RecruitingNCT07406698STEP-INUpdated Feb 12, 2026

Strategic Timing of Endoscopic Interventions in Infected Necrotizing Pancreatitis

An interventional study of EUS-guided transluminal drainage of necrotic collection in Pancreatitis, Acute Necrotizing, sponsored by Orlando Health, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-12.

Sponsored by Orlando Health, Inc. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Pancreatitis, Acute Necrotizing with a site in United States — 3 open to participants now, 4 under way, none of them phase 3. Pancreatitis, Acute Necrotizing · United States.

Planned enrollment
2nd of 13
104 · median 40
Started
2026
with 1 other
No phase
11 of 20
2 open now
Registered
20th of 20
by date
Lead sponsor
3 of 20
Orlando Health, Inc.

Among the 20 studies in Pancreatitis, Acute Necrotizing with a site in United States, this one is the 2nd largest by planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2026, is one of 11 with no phase, and was the 20th registered.

Pancreatitis, Acute Necrotizing

75 studies on the registry are indexed under Pancreatitis, Acute Necrotizing; 20 are open to participants now.

Browse Pancreatitis, Acute Necrotizing studies →

Open to participants now

3 of the 20 studies in Pancreatitis, Acute Necrotizing with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Pancreatitis, Acute Necrotizing studies recruiting now, 9 (75%) set no upper age limit and 3 (25%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Pancreatitis, Acute Necrotizing with a site in United States, or all of them as a file.
02

Study summary

Pancreatic necrosis complicates approximately 20-30% of severe acute pancreatitis cases. While many collections resolve without intervention, persistent symptomatic collections-particularly when infected-are associated with significant morbidity and mortality and frequently require procedural management. Current guidelines recommend delaying intervention until collections are fully walled off, typically around four weeks. However, in clinical practice, many patients deteriorate before this window is reached.

Prospective data from our institution, supported by recent meta-analyses, suggest that early intervention using modern endoscopic techniques can be performed safely, even when undertaken within the first four weeks of disease onset. We believe that, in appropriately selected patients, early endoscopic intervention may prevent clinical deterioration, reduce complications, shorten hospital stay, and decrease overall healthcare utilization compared with a delayed approach.

To formally evaluate this strategy, an international, multicenter randomized trial is being conducted, entitled Strategic Timing of Endoscopic Procedural Interventions in Infected Necrotizing Pancreatitis (STEP-IN Trial).

Read the detailed description

Acute pancreatitis imposes a significant burden on the US health-care system, resulting in approximately 300,000 hospital admissions annually and generating costs exceeding $2 billion. Necrotizing pancreatitis develops in approximately 20 to 30% of patients with acute pancreatitis. It can mature into a contained necrotic collection, typically four weeks into the disease course. While some collections may resolve without an intervention, persistent collections can result in symptoms such as pain, abdominal fullness restricting nutrition, vomiting due to gastric outlet obstruction, obstructive jaundice due to a large collection in the pancreatic head, new-onset or persisting organ failure, continued unwellness or infection that is associated with a mortality of 15-20%, and requires drainage and necrosectomy.

International guidelines recommend that, when possible, treatment should be delayed in patients with suspected or confirmed infected necrotizing pancreatitis, to allow for the collection to be walled-off with better demarcation and liquefaction of the necrosis, which generally takes around 4 weeks. The main rationale for postponement of an invasive intervention is to prevent complications, but this rationale originated from an era when open surgical necrosectomy was performed.

Recently, there has been a shift away from open surgery towards minimally invasive treatment approaches. The current standard approach for treatment is a minimally invasive step-up approach with percutaneous catheter or transluminal endoscopic drainage as the first step, followed by video-assisted retroperitoneal/sinus-tract or transgastric necrosectomy. The development of cautery-enhanced lumen-apposing metal stents (LAMS) for endoscopic drainage has significantly simplified the technical aspects of the procedure that facilitates its performance even in very sick patients.

Although international guidelines recommend postponing treatment until 4-weeks when the necrosis is better demarcated, in an international survey of expert pancreatologists, 45% of the respondents reported that they recommend immediate catheter drainage as soon as infected pancreatic and peripancreatic necrosis is diagnosed. In addition, a recent clinical practice guideline from the American Gastroenterological Association states that catheter drainage should be strongly considered when there is a concern of infection, even in the early phase of disease. However, a multicenter, randomized trial did not show superiority for immediate over postponed catheter drainage in reducing complications in patients with infected necrotizing pancreatitis.

Prospective data from our institution and from the meta-analysis suggest that interventions can be undertaken safely adopting state-of-the-art endoscopic methods even when the onset of pancreatitis is less than 4 weeks. Our data also suggest that although a significant proportion of patients undergoing early interventions (adopting an endoscopic approach) do not have a fully encapsulated collection, their treatment outcomes are not negatively impacted by such approach. If an early intervention, adopting an endoscopic approach, can be undertaken safely, it potentially can prevent further clinical deterioration and therefore complications, decrease length of hospitalization as patients may not have to wait for 3 to 4 weeks and overall treatment costs as compared to postponing the intervention until 4-weeks when the necrosis is fully walled-off.

The STEP-IN trial therefore is a natural step in the advancement of our understanding of timing of interventions in necrotizing pancreatitis as it answers an important clinical question: can early interventions be undertaken safely without subjecting patients to an arbitrary time frame of 4-weeks? In this study we challenge the existing paradigm of delayed intervention in attempt to further improve the clinical outcomes in patients with infected necrotizing pancreatitis.

03

Conditions studied

  • Pancreatitis, Acute Necrotizing

Keywords

  • Endoscopic ultrasound
  • Drainage
  • Necrotic collection
  • Timing of intervention
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years
  2. Patients with symptomatic necrotic collection diagnosed on MRI or CT abdomen/pelvis, defined as fluid collection in the setting of documented pancreatic necrosis that contains necrotic material and encased within a partial or complete wall.
  3. Documented or suspected infected necrotizing pancreatitis 1) Documented infected necrotizing pancreatitis, defined as: i. Positive culture obtained with percutaneous fine needle aspiration from the pancreatic necrotic collection (if intervention is undertaken ≤14 days of onset of acute pancreatitis) ii. OR gas in the necrotic collection on imaging at any time. 2) Suspected infected necrotizing pancreatitis, if >14 days after onset of disease, defined as: i. Persistent organ failure in patients admitted to the ICU ii. OR presence of at least three of the following six clinical/laboratory parameters (SIRS criteria or elevated CRP or elevated procalcitonin) with no other infection focus. These clinical criteria are considered sufficiently reliable only after the initial 14 days of acute pancreatitis:

    1. Temperature >100.4 °F or \<96.8 °F
    2. Heart rate > 90 beats/min
    3. Respiratory rate >20 breaths/min or PaCO2 \< 32 mmHg
    4. WBC count >12,000/mm³, or \<4,000/mm³, or more than 10% immature band cells
    5. CRP ≥ 30mg/L
    6. Procalcitonin ≥ 1ng/mL
  4. Endoscopic drainage of the necrotic collection is technically feasible as deemed by the treating physician.

Exclusion criteria

Exclusion Criteria:

  1. Age \< 18 years
  2. > 26 days after the onset of acute pancreatitis
  3. Indication for emergency laparotomy for abdominal catastrophe (e.g. bleeding, bowel perforation, abdominal compartment syndrome).
  4. Necrotic collection is not amenable for endoscopic intervention.
  5. Pregnancy.
  6. Unable to obtain from the patient or legally authorized representative.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
104 participants (estimated)

Study arms

  • Active comparator
    Early endoscopic intervention in infected necrotizing pancreatitis

    In the early treatment group, EUS-guided drainage is undertaken within 72 hours of randomization, earlier than 28 days after the onset of acute pancreatitis.

    Procedure: EUS-guided transluminal drainage of necrotic collection

  • Active comparator
    Postponed endoscopic intervention in infected necrotizing pancreatitis

    In the postponed treatment group, EUS-guided drainage is undertaken only from 28 days after the onset of acute pancreatitis when the collection is fully or predominantly walled-off (encapsulated).

    Procedure: EUS-guided transluminal drainage of necrotic collection

Interventions

  • ProcedureEUS-guided transluminal drainage of necrotic collection

    EUS-guided drainage of the necrotic collection is performed by placement of a metal stent within the dominant collection.

06

What researchers measure

Primary outcomes

  1. Composite of major complications or death

    Proportion of patients experiencing a major complication or death. Major complications comprise new onset organ failure, new onset systemic dysfunction, enteral or pancreatic-cutaneous fistula, intraabdominal bleeding, or visceral perforation.

    Time frame: 6 months

Secondary outcomes

  1. Mortality

    Proportion of patients with mortality from any cause

    Time frame: 6 months

  2. Major complications

    Proportion of patients experiencing major complications. Major complications comprise new onset organ failure (respiratory, cardiovascular, renal, gastrointestinal, hepatic, hematologic, neurologic, or metabolic failure), new onset systemic dysfunction, enteral or pancreatic-cutaneous fistula, intraabdominal bleeding, or visceral perforation

    Time frame: 6 months

  3. New onset single and multiple organ failure

    Proportion of patients with new onset failure of at least one organ system

    Time frame: 6 months

  4. New onset systemic dysfunction

    Proportion of patients with worsening of any pre-existing medical condition

    Time frame: 6 months

  5. Enterocutaneous and pancreatic fistula

    Proportion of patients with enterocutaneous fistula or pancreatic fistula. Enterocutaneous fistula is the formation of a fistula between the small bowel or colon and skin as indicated by feculent output from a percutaneous catheter or surgical wound site, confirmed on imaging or surgery. Pancreatic fistula is the formation of a fistula between the pancreas and skin as indicated by amylase-rich fluid output from a percutaneous catheter or surgical wound site, persisting after 3 months, and requiring specific treatment that include parenteral or enteral nutrition, antibiotics, somatostatin analogues and minimally invasive drainage.

    Time frame: 6 months

  6. Intraabdominal bleeding

    Proportion of patients with intraabdominal bleeding. Intraabdominal bleeding is defined as bleeding within the intraabdominal cavity or gastrointestinal tract requiring interventional procedure

    Time frame: 6 monthts

  7. Visceral perforation

    Proportion of patients with visceral perforation. Visceral perforation is defined as the perforation of a visceral organ requiring interventional procedure

    Time frame: 6 months

  8. Incisional hernia

    Proportion of patients with incisional hernia. Incisional hernia is defined as herniation of intraabdominal structures through an area of weakness in the abdominal fascia, requiring surgical intervention or persisting at 6-month follow-up

    Time frame: 6 months

  9. Surgical site infection

    Proportion of patients with surgical site infection. Surgical site infection is defined as the infection in superficial or deep layers of the abdominal wall at the site of prior intervention, as evident by the presence of purulent drainage or abscess on physical examination, imaging and/or requiring intervention

    Time frame: 6 months

  10. New onset diabetes

    Proportion of patients with new onset diabetes. New onset diabetes is defined as new onset elevation in fasting plasma glucose ≥ 126 mg/dL, 2-hour plasma glucose ≥ 200 mg/dL after an oral glucose tolerance test or HbA1c ≥ 6.5%

    Time frame: 6 months

  11. New diagnosis of exocrine pancreatic insufficiency

    Proportion of patients with new diagnosis of exocrine pancreatic insufficiency. Exocrine pancreatic insufficiency is defined as fecal elastase level \< 200μg/g in patients not previously taking pancreatic enzyme supplements

    Time frame: 6 months

  12. Procedure-related adverse events

    Proportion of patients with any adverse event resulting from endoscopic or surgical intervention

    Time frame: 6 months

  13. Disease-related adverse events

    Proportion of patients with any adverse event resulting from necrotizing pancreatitis

    Time frame: 6 months

  14. Number of interventions

    Number of interventions performed for treatment of infected necrotizing pancreatitis including endoscopic, surgical and radiological interventions

    Time frame: 6 months

  15. Length of hospitalization

    Length of hospitalization, including length of ICU stay

    Time frame: 6 months

  16. Readmissions

    Proportion of patients with hospital admissions due to underlying disease or procedure-related adverse events

    Time frame: 6 months

  17. Presence of systemic inflammatory response syndrome (SIRS) at 72 hours post-index intervention

    Proportion of patients with positive SIRS at 72 hours post-index procedure. Positive SIRS is defined by the presence of at least two of the following four criteria: 1. Body temperature \>100.4 °F or \< 96.8 °F 2. Heart rate \> 90 beats/minute 3. Respiratory rate \> 20 breaths/minute or PaCO2 \< 32mmHg 4. White blood cell count \> 12 or \< 4 x109/L or \> 10% immature neutrophils

    Time frame: 72 hours

  18. New onset systemic inflammatory response syndrome (SIRS) at 72 hours post-index intervention

    Proportion of patients with new onset SIRS at 72 hours post-index intervention. Positive SIRS is defined by the presence of at least two of the following four criteria: 1. Body temperature \>100.4 °F or \< 96.8 °F 2. Heart rate \> 90 beats/minute 3. Respiratory rate \> 20 breaths/minute or PaCO2 \< 32mmHg 4. White blood cell count \> 12 or \< 4 x109/L or \> 10% immature neutrophils

    Time frame: 72 hours

  19. Resolution and improvement of systemic inflammatory response syndrome (SIRS) at 72 hours post-index intervention

    Proportion of patients with resolution of SIRS at 72 hours post-index intervention. Positive SIRS is defined by the presence of at least two of the following four criteria: 1. Body temperature \>100.4 °F or \< 96.8 °F 2. Heart rate \> 90 beats/minute 3. Respiratory rate \> 20 breaths/minute or PaCO2 \< 32mmHg 4. White blood cell count \> 12 or \< 4 x109/L or \> 10% immature neutrophils

    Time frame: 72 hours

  20. Technical success

    Rate of technical success. Technical success is defined as the successful completion of EUS-guided drainage of the necrotic collection

    Time frame: 6 months

  21. Treatment success

    Rate of treatment success. Treatment success is defined as the resolution of necrotic collection on CT scan in association with clinical resolution of symptoms at 6 months from index intervention

    Time frame: 6 months

  22. Health-related quality of life (HRQoL)

    Health-related quality of life (HRQoL) scores as assessed by the Medical Outcomes Study 36-Item Short-Form General Health Survey (SF-36)

    Time frame: 6 months

  23. Overall treatment costs

    Overall treatment costs from admission until hospital discharge. All relevant costs pertaining to treatment will be taken into consideration - procedure costs, cost of inpatient hospital stay (from date of procedure to discharge), cost of medications, cost of materials, cost of anesthesia, cost of pharmacy and cost of imaging studies.

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Jun 2029, 41 months later.

Of 20 interventional studies with no phase under Pancreatitis, Acute Necrotizing, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 36. This study's planned 41 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2026
First posted
Feb 12, 2026
StartEst.
Jan 28, 2026
Primary completionEst.
Jun 30, 2029
CompletionEst.
Dec 31, 2029
Last update
Feb 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07406698
Lead sponsor
Orlando Health, Inc.
Responsible party
Sponsor
First posted
Feb 12, 2026
Start date
Jan 28, 2026 (estimated)
Primary completion
Jun 30, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Feb 12, 2026

Study contacts

Ji Young Bang, MD MPH
Contact
jiyoung.bang@orlandohealth.com
321-842-2273
Barbara J Broome
Contact
Barbara.Broome@orlandohealth.com
321-841-3742
Ji Young Bang, MD MPH
principal investigator · Orlando Health

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion